Related references
Note: Only part of the references are listed.Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
C. K. Lee et al.
BRITISH JOURNAL OF CANCER (2011)
Prediction Models: Revolutionary in Principle, But Do They Do More Good Than Harm?
Andrew J. Vickers
JOURNAL OF CLINICAL ONCOLOGY (2011)
Historical cross-trial comparisons for competing treatments in advanced breast cancer - An empirical analysis of bias
C. K. Lee et al.
EUROPEAN JOURNAL OF CANCER (2010)
Comparison of Error Rates in Single-Arm Versus Randomized Phase II Cancer Clinical Trials
Hui Tang et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer
M. S. Carey et al.
GYNECOLOGIC ONCOLOGY (2008)
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
Edward L. Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gene-expression profiling in epithelial ovarian cancer
Panagiotis A. Konstantinopoulos et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond
Michael J. Pencina et al.
STATISTICS IN MEDICINE (2008)
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:: An intergroup trial of the AGO-OVAR, the NCICCTG, and the EORTC GCG
Jacobus Pfisterer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer
MR Stockler et al.
BRITISH JOURNAL OF CANCER (2006)
Individual survival time prediction using statistical models
R Henderson et al.
JOURNAL OF MEDICAL ETHICS (2005)
Cancer patient preferences for communication of prognosis in the metastatic setting
RG Hagerty et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)
GJS Rustin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
AN Gordon et al.
GYNECOLOGIC ONCOLOGY (2004)
Overall C as a measure of discrimination in survival analysis:: model specific population value and confidence interval estimation
MJ Pencina et al.
STATISTICS IN MEDICINE (2004)
A systematic review of physicians' survival predictions in terminally ill cancer patients
P Glare et al.
BRITISH MEDICAL JOURNAL (2003)
Share Paper
